Lancet Robotics Completes Series A+ Financing to Accelerate Domestic Multi-Specialty Surgical Robot Deployment

Lancet Robot is dedicated to providing healthcare institutions with comprehensive, end-to-end artificial intelligence surgical robot solutions. After years of technological accumulation and market expansion, Lancet Robot has successfully established a complete product and service ecosystem for surgical robots, covering key clinical departments and fields such as joint replacement, spine trauma, dental implantology, neurosurgery, and vascular intervention. To date, the company has obtained five Class III medical device registration certificates—including those for the hip-and-knee integrated joint replacement surgical robot, joint replacement navigation system, dental implant surgical robot, and dental implant navigation system—as well as one U.S. FDA 510(k) clearance and two Class II medical device registration certificates. It has also received numerous national and provincial awards and honors, with nearly 400 intellectual property rights filed, including 166 invention patents. Furthermore, several cross-departmental surgical robot products, such as those for minimally invasive tumor intervention and neurosurgery, are steadily advancing through the NMPA and FDA registration processes, further demonstrating Lancet Robot’s firm commitment and strong capability to continuously translate Chinese solutions for cross-departmental surgical robots, driven by innovation rooted in addressing clinical pain points.

Leveraging its robust independent R&D capabilities, Shenzhen Lancet Robot Co., Ltd. has continuously achieved breakthroughs in core technologies, successfully realizing 100% domestic production of surgical robots—from key algorithms and mass-production processes to core components. This achievement has significantly reduced both manufacturing costs and end-user prices for surgical robots, effectively breaking down the price barriers associated with high-end medical equipment and accelerating the comprehensive substitution of imported high-end surgical robots with domestically produced alternatives. By offering cost-effective intelligent devices, the company extends high-quality medical services to a broader patient population. This initiative has not only promoted the widespread adoption of surgical robots in top-tier tertiary hospitals but also facilitated their deep penetration into municipal, district, and county-level public hospitals as well as private medical institutions, substantially enhancing the surgical technical standards and service capabilities of grassroots healthcare facilities. Currently, Lancet Robot’s products have been deployed in dozens of hospitals, making robot-assisted surgery readily accessible at the primary care level. This breaks the paradigm where high-end equipment serves only a select few patients, provides strong support for the balanced development of medical resources, and drives the transition of robot-assisted surgery from “concentration in a few hospitals” to “universal adoption across hospitals at all levels,” truly achieving inclusive access to advanced medical technology.

Amidst a global surgical robotics market dominated by international giants, Lancet Robot has adopted a dual-drive strategy of “FDA clearance + emerging markets.” As one of the first Chinese surgical robotics companies to secure U.S. FDA 510(k) clearance for joint replacement surgical robots, Lancet Robot has driven overseas market expansion through continuous technological breakthroughs. By focusing on emerging markets with scarce medical resources, it has pioneered a model for the global export of Chinese-made joint replacement surgical robots. The company has established a presence in strategic regions including Southeast Asia, South Asia, and South America, precisely addressing local demands for intelligent healthcare upgrades. To date, it has accumulated over 20 overseas orders and completed multiple robot-assisted surgeries at overseas clinical centers, providing a highly referenceable case study for globalization within the industry.

Mr. Huang Zhijun, Chairman of Lancet Robot, stated:We extend our sincere gratitude to Yuehu Fund for its high recognition and strong support of Lancet Robot. Within just a few years, through independent research and development, the company has overcome critical technological bottlenecks, achieving 100% domestic production of core components for surgical robots. This success has effectively broken the technological monopoly and commercial dominance held by imported products. Leveraging this round of financing, Lancet Robot will accelerate the regulatory approval, market launch, and expansion of indications for its multi-disciplinary domestically produced surgical robots, relying on its integrated medical-engineering innovation system and comprehensive technological breakthrough capabilities. The company is committed to promoting the adoption of domestic surgical robots in primary healthcare institutions, empowering a broader range of grassroots hospitals and patients with intelligent equipment, while actively expanding its global footprint. We believe that this financing will help Lancet Robot accelerate new product R&D, expand production capacity, and comprehensively strengthen its commercial layout, thereby fast-tracking its emergence as an industry benchmark. This will continuously drive the intelligent development of medical surgical equipment, provide higher-quality and more advanced medical services to patients, and inject Chinese strength into the global intelligent healthcare industry.

Yuehu Fund stated:We are delighted to participate in this round of investment in Lancet Robot. Under the technical leadership of its team of academicians, Lancet Robot has achieved a “dual certification” breakthrough from both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) in the field of robotic-assisted hip and knee joint replacement surgery. The RobPath-THA robot has further raised industry standards with a 96.6% accuracy rate in acetabular component placement. Its open-platform design breaks down technical barriers, while its closed-loop business model of “equipment + consumables + services” deeply integrates superior technological capabilities with a commitment to making technology accessible for public benefit, offering a new paradigm for the development of medical technology.

Lancet Robot, established in 2018, is a Zhejiang-based enterprise recognized as a specialized and sophisticated SME. It has strategically positioned itself across four high-value surgical sectors: spine/trauma, joint replacement, dental implantology, and vascular intervention. The core members of its R&D team are graduates of prestigious domestic and international universities, specializing in science, engineering, and clinical medicine. With strong expertise in medical-engineering integration and solid technical capabilities, the company has established stable and efficient research and innovation platforms that integrate industry, academia, research, and clinical practice in collaboration with professional institutions such as Nanjing Drum Tower Hospital (Affiliated to Nanjing University Medical School) and the Second Affiliated Hospital of Zhejiang University School of Medicine. The company is committed to providing hospitals with comprehensive solutions covering the entire surgical workflow, including AI-assisted diagnosis, personalized surgical planning, robotic surgical navigation systems, and postoperative assessment.

As the fund manager of the Jianhu Yuehu Emerging Industry Fund, Wutong Capital leverages Jianhu’s robust industrial ecosystem and its deep professional expertise in the medical technology sector to accurately identify the development potential of Lancet Robot. Looking ahead, Wutong Capital will fully utilize its role as a capital link, combine the resource advantages of the Jianhu Robotics Industrial Base, and continue to empower the long-term growth of Lancet Robot. By working together to advance medical technology progress, it aims to contribute to enhancing public well-being.